• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Simultaneous detection of methylation and genetic variations of BCR-ABL1 gene by nanopore Cas9-targeted sequencing.

作者信息

Xie Shuilian, Yang Ying, Zhang Junjie, Zhu Menglin, Li Wang, Li Mengting, Chen Yijian, Li Hailiang, Lun Weidan, Chong Weelic, Wan Shaogui

机构信息

Center for Molecular Pathology, Department of Basic Medicine, Gannan Medical University, Ganzhou, Jiangxi 341000, China.

Department of Hematology, First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi 341000, China.

出版信息

Genes Dis. 2023 Dec 6;11(6):101190. doi: 10.1016/j.gendis.2023.101190. eCollection 2024 Nov.

DOI:10.1016/j.gendis.2023.101190
PMID:39157453
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11327521/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f22/11327521/94c49e758f9b/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f22/11327521/94c49e758f9b/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f22/11327521/94c49e758f9b/gr1.jpg

相似文献

1
Simultaneous detection of methylation and genetic variations of BCR-ABL1 gene by nanopore Cas9-targeted sequencing.通过纳米孔Cas9靶向测序同时检测BCR-ABL1基因的甲基化和基因变异
Genes Dis. 2023 Dec 6;11(6):101190. doi: 10.1016/j.gendis.2023.101190. eCollection 2024 Nov.
2
Imatinib independent aberrant methylation of NOV/CCN3 in chronic myelogenous leukemia patients: a mechanism upstream of BCR-ABL1 function?伊马替尼治疗的慢性髓系白血病患者 NOV/CCN3 异常甲基化：BCR-ABL1 功能的上游机制？
Cell Commun Signal. 2019 Apr 23;17(1):38. doi: 10.1186/s12964-019-0350-6.
3
Creation of Philadelphia chromosome by CRISPR/Cas9-mediated double cleavages on BCR and ABL1 genes as a model for initial event in leukemogenesis.利用 CRISPR/Cas9 介导的 BCR 和 ABL1 基因双切割构建费城染色体模型，模拟白血病发生的初始事件。
Cancer Gene Ther. 2023 Jan;30(1):38-50. doi: 10.1038/s41417-022-00522-w. Epub 2022 Aug 23.
4
Breakpoint mapping of a t(9;22;12) chronic myeloid leukaemia patient with e14a3 BCR-ABL1 transcript using Nanopore sequencing.利用纳米孔测序对一名携带 e14a3 BCR-ABL1 转录本的 t(9;22;12) 慢性髓性白血病患者进行断点映射。
J Gene Med. 2021 Jan;23(1):e3276. doi: 10.1002/jgm.3276. Epub 2020 Oct 1.
5
Cancer Biomarkers Discovery of Methylation Modification With Direct High-Throughput Nanopore Sequencing.基于直接高通量纳米孔测序的癌症生物标志物甲基化修饰发现
Front Genet. 2021 May 26;12:672804. doi: 10.3389/fgene.2021.672804. eCollection 2021.
6
In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants.在接受二线酪氨酸激酶抑制剂治疗的慢性髓性白血病患者中，在出现警示时对BCR-ABL1进行深度测序可能有助于灵敏检测新出现的耐药突变体。
BMC Cancer. 2016 Aug 2;16:572. doi: 10.1186/s12885-016-2635-0.
7
Novel BCR-ABL1 fusion and leukemic mutations of SETBP1, PAX5, and TP53 detected by next generation sequencing in chronic myeloid leukemia.通过下一代测序在慢性髓性白血病中检测到的新型BCR-ABL1融合以及SETBP1、PAX5和TP53的白血病突变。
Cancer Biol Ther. 2016 Oct 2;17(10):1003-1009. doi: 10.1080/15384047.2016.1219821. Epub 2016 Sep 10.
8
Mutational analysis in BCR-ABL1 positive leukemia by deep sequencing based on nanopore MinION technology.基于纳米孔MinION技术的深度测序对BCR-ABL1阳性白血病进行突变分析。
Exp Mol Pathol. 2017 Aug;103(1):33-37. doi: 10.1016/j.yexmp.2017.06.007. Epub 2017 Jun 27.
9
Elucidating Hexanucleotide Repeat Number and Methylation within the X-Linked Dystonia-Parkinsonism (XDP)-Related SVA Retrotransposon in with Nanopore Sequencing.利用纳米孔测序阐明 X 连锁肌张力障碍-帕金森病（XDP）相关 SVA 反转录转座子中的六核苷酸重复数和甲基化。
Genes (Basel). 2022 Jan 11;13(1):126. doi: 10.3390/genes13010126.
10
ABL1 methylation in Ph-positive ALL is exclusively associated with the P210 form of BCR-ABL.Ph 阳性急性淋巴细胞白血病中的 ABL1 甲基化仅与 BCR-ABL 的 P210 形式相关。
Leukemia. 2001 Apr;15(4):575-82. doi: 10.1038/sj.leu.2402026.

本文引用的文献

1
Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia-From Molecular Mechanisms to Clinical Relevance.慢性髓性白血病中对酪氨酸激酶抑制剂的耐药性——从分子机制到临床相关性
Cancers (Basel). 2021 Sep 26;13(19):4820. doi: 10.3390/cancers13194820.
2
Targeted nanopore sequencing with Cas9-guided adapter ligation.靶向纳米孔测序与 Cas9 引导的接头连接。
Nat Biotechnol. 2020 Apr;38(4):433-438. doi: 10.1038/s41587-020-0407-5. Epub 2020 Feb 10.
3
Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.
酪氨酸激酶抑制剂时代的慢性髓性白血病：分子靶向治疗的不断演变模式
Mol Diagn Ther. 2016 Aug;20(4):315-33. doi: 10.1007/s40291-016-0208-1.
4
Increased BCR promoter DNA methylation status strongly correlates with favorable response to imatinib in chronic myeloid leukemia patients.慢性髓性白血病患者中，BCR启动子DNA甲基化状态增加与对伊马替尼的良好反应密切相关。
Oncol Lett. 2011 Jan;2(1):181-187. doi: 10.3892/ol.2010.208. Epub 2010 Nov 23.